Treating Melasma — A Multi-Modal Approach

Last updated: 5 March 2026

Melasma is one of the most challenging pigmentary disorders in dermatology, affecting predominantly women and often proving resistant to single-modality treatment. This guide presents an evidence-based multi-modal approach that addresses the multiple pathogenic mechanisms underlying this persistent condition.

Reviewed by the Axiom Aesthetics Clinical Team | Last updated: February 2026

Understanding Melasma

Melasma is a chronic acquired pigmentary disorder characterised by symmetric brown to grey-brown patches on sun-exposed areas, particularly the face. It affects women 9 times more often than men and is more prevalent in darker skin types (Fitzpatrick III-VI). Three patterns are recognised: centrofacial (most common, affecting forehead, cheeks, nose, upper lip, and chin), malar (cheeks and nose only), and mandibular (jawline).

Pathogenesis: More Than Just Melanocytes

Melasma was once considered a simple melanocyte overactivity disorder, but current understanding recognises it as a complex interaction between melanocytes (producing excess melanin), keratinocytes (transferring and distributing melanin abnormally), fibroblasts (producing melanogenic factors), mast cells (promoting inflammation and vascularisation), vascular endothelium (increased vascularity in lesional skin), and basement membrane (disrupted barrier allowing melanin deposition into dermis). This multi-cellular pathogenesis explains why single-target treatments often produce disappointing results.

The Multi-Modal Treatment Approach

Tier 1: Sun Protection (Essential Foundation)

Strict photoprotection is non-negotiable. Broad-spectrum SPF 50 plus, reapplied every 2 hours, using formulations containing iron oxides which block visible light (a melasma trigger that conventional sunscreens miss). Visible light from screens and indoor lighting can trigger melasma, making tinted sunscreens with iron oxide essential even indoors. Without strict sun protection, all other treatments will fail.

Tier 2: Topical Depigmentation

First-line topical therapy includes hydroquinone (2-4 percent), the most effective single depigmenting agent, used in cycles of 3-4 months on, 2-3 months off. Triple combination cream (hydroquinone, tretinoin, and a mild corticosteroid) remains the gold standard topical, with superior efficacy to any individual agent. Maintenance agents for off-hydroquinone periods include azelaic acid (15-20 percent), tranexamic acid (topical or oral), vitamin C, arbutin, kojic acid, and niacinamide.

Tier 3: Oral Tranexamic Acid

Oral tranexamic acid (250mg twice daily) has emerged as a game-changing treatment for melasma. It works by inhibiting plasminogen activation, reducing melanocyte-stimulating factors, and modulating the vascular component. Multiple RCTs demonstrate significant improvement with a favourable safety profile. Contraindications include history of thromboembolism and concurrent use of oral contraceptives containing oestrogen.

Tier 4: Procedural Treatments

Superficial chemical peels (glycolic, salicylic, or lactic acid) can accelerate topical therapy effects. Microneedling improves topical penetration and stimulates controlled remodelling. Low-fluence Q-switched Nd:YAG (laser toning) has shown benefit in some studies but carries risk of rebound hyperpigmentation. Picosecond laser with holographic optic produces less thermal damage and may have a better safety profile. All procedural treatments carry PIH risk in melasma-prone skin and should be approached conservatively.

The Importance of Maintenance

Melasma is a chronic condition that requires ongoing management. Relapse rates after treatment cessation are high, particularly with sun exposure. A long-term maintenance strategy including daily tinted SPF, rotating depigmenting agents, and periodic professional treatments is essential for sustained improvement. Setting this expectation from the outset improves patient satisfaction and adherence.

Frequently Asked Questions